(VIANEWS) – Shares of Exact Sciences (NASDAQ: EXAS) jumped by a staggering 28.39% in 21 sessions from $63.41 at 2023-05-01, to $81.41 at 15:24 EST on Wednesday, following the last session’s downward trend. NASDAQ is sliding 0.55% to $12,945.46, after three successive sessions in a row of gains.
Exact Sciences’s last close was $81.14, 5.45% below its 52-week high of $85.82.
About Exact Sciences
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Earnings Per Share
As for profitability, Exact Sciences has a trailing twelve months EPS of $-2.89.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -16.36%.
More news about Exact Sciences (EXAS).
